AbbVie Inc. is 216.1x more valuable than Stoke Therapeutics, Inc. by market capitalization ($397.12 B vs $1.84 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | STOK | ABBV |
|---|---|---|
| Market cap | $1.84 B | $397.12 B |
| US-listed rank | #2166 | #30 |
| Revenue (latest FY) | $184.42M | $61.16B |
| Net income (latest FY) | -$6.88M | $4.23B |
| Net margin | -3.7% | 6.9% |
| P/E (trailing FY) | - | 94.0 |
| SEC filings | 588 | 1,008 |
AbbVie Inc. is 216.1x more valuable than Stoke Therapeutics, Inc. by market capitalization ($397.12 B vs $1.84 B).
In their latest fiscal years, Stoke Therapeutics, Inc. reported $184.42M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Stoke Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.